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Ischaemic heart disease is one of the leading causes of morbidity and mortality worldwide. The development of
cardioprotective therapeutic agents remains a partly unmet need and a challenge for both medicine and industry, with
significant financial and social implications. Protection of the myocardium can be achieved by mechanical vascular occlusions
such as preconditioning (PC), when brief episodes of ischaemia/reperfusion (I/R) are experienced prior to ischaemia;
postconditioning (PostC), when the brief episodes are experienced at the immediate onset of reperfusion; and remote
conditioning (RC), when the brief episodes are experienced in another vascular territory. The elucidation of the signalling
pathways, which underlie the protective effects of PC, PostC and RC, would be expected to reveal novel molecular targets for
cardioprotection that could be modulated by pharmacological agents to prevent reperfusion injury. Gasotransmitters
including NO, hydrogen sulphide (H2S) and carbon monoxide (CO) are a growing family of regulatory molecules that affect
physiological and pathological functions. NO, H2S and CO share several common properties; they are beneficial at low
concentrations but hazardous in higher amounts; they relax smooth muscle cells, inhibit apoptosis and exert
anti-inflammatory effects. In the cardiovascular system, NO, H2S and CO induce vasorelaxation and promote cardioprotection.
In this review article, we summarize current knowledge on the role of the gasotransmitters NO, H2S and CO in myocardial I/R
injury and cardioprotection provided by conditioning strategies and highlight future perspectives in cardioprotection by NO,
H2S, CO, as well as their donor molecules.
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Introduction: cardioprotection and
gasotransmitters
Ischaemic heart disease is one of the leading causes of mor-
tality and morbidity in the industrialized societies. Therefore,
therapeutic strategies to protect the ischaemic myocardium
have been extensively studied. Ischaemic preconditioning
(PC), postconditioning (PostC) and remote conditioning (RC)
of myocardium are well-described adaptive responses in
which brief exposure to ischaemia/reperfusion (I/R) prior to
ischaemia (PC), at the immediate onset of reperfusion (PostC)
or in a remote organ prior to, during or at reperfusion after
sustained ischaemia (RC), respectively, leads to cardioprotec-
tion characterized by reduction of infarct size and occurrence
of arrhythmias, and attenuation of cardiac dysfunction.
Although the cardioprotective effect of conditioning strate-
gies have been proven in several species including humans, it
seems that the presence of cardiovascular risk factors,
co-morbidities and their medications may interfere with car-
dioprotective signalling pathways (for extensive reviews, see
Ferdinandy et al., 2007; Ovize et al., 2010; Hausenloy et al.,
2013; Ferdinandy et al., 2014). The cellular mechanism of
cardioprotective pathways are not exactly known, although
several signal transduction cascades have been suggested as
reviewed elsewhere (Ferdinandy et al., 2007; Heusch et al.,
2008; Ovize et al., 2010; Hausenloy et al., 2013; Heusch,
2013). Better understanding of the underlying signal trans-
duction of ischaemic conditioning strategies may provide an
important paradigm for cardioprotection and their transla-
tion to clinical use of pharmacological interventions
(Hausenloy et al., 2013; Heusch, 2013). Various ligands
occupy the specific surface receptors and then the cardiopro-
tective modalities start with intracellular signalling transduc-
tion, which among others includes redox signalling by
reactive oxygen species (ROS), S-nitrosylation by NO and its
derivatives, S-sulphydration by hydrogen sulphide and
O-linked glycosylation with β-N-acetylglucosamine. All these
modalities interact and regulate an entire pathway, thus
influencing each other. For instance, enzymes can be phos-
phorylated and/or nitrosylated in specific and/or different
site(s), with consequent increase or decrease in their specific
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activity. The cardioprotective signalling pathways are
thought to converge on mitochondria, and various mito-
chondrial proteins have been identified as targets of these
post-transitional modifications (see Heusch et al., 2008;
Pagliaro et al., 2011).
Gasotransmitters are a growing family of regulatory mol-
ecules involved in multilevel regulation of physiological and
pathological functions in mammalian tissues. It is now
widely recognized that the gasotransmitters NO, along with
hydrogen sulphide (H2S) and carbon monoxide (CO), are
involved in a multitude of physiological functions (Caliendo
et al., 2010; Szabo, 2010; Peers and Steele, 2012). In the car-
diovascular system, the regulatory role of NO and H2S
includes vasorelaxation, stimulation of angiogenesis and car-
dioprotection (Szabo, 2010; Coletta et al., 2012), and that of
CO includes relaxation of coronary vascular smooth muscle
and cardioprotection (Muchova et al., 2007).
The synthesis and major metabolic pathways of NO are
described in detail elsewhere (Moncada et al., 1997; Pacher
et al., 2007; Rassaf et al., 2014), including the current Themed
Issue (see Csonka et al., 2015). In brief, NO is produced in
most of the mammalian tissues and cells by both enzymic
and non-enzymic reactions. Three isoforms of NOS have
been described, neuronal (nNOS), endothelial (eNOS) and
inducible (iNOS) isoforms. NOS activity is regulated by
compartmentalization, substrate and co-factor availability,
endogenous inhibitors, as well as transcriptional, post-
transcriptional and post-translational modulations. The
formation of NO by NOS-independent enzymic and non-
enzymic reduction of nitrite/nitrate from dietary and
endogenous sources becomes especially important during
ischaemia when pH becomes acidic and oxygen-dependent
NOS activity is limited. The major biological reactions of NO
includes oxidation to nitrite and nitrate as well as its reaction
with superoxide to yield peroxynitrite anion (ONOO−), a reac-
tive nitrating and nitrosating agent. Important molecular
targets of NO include metalloenzymes such as soluble gua-
nylate cyclase (GC), haemoglobin and cytochromes, along
with S-nitros(yl)ation of thiols yielding S-nitrosothiols (see
Ferdinandy and Schulz, 2003; Pacher et al., 2007; Tennyson
and Lippard, 2011; Radi, 2013).
H2S is generated from endogenous sources and is physi-
ologically present in blood and other tissues. Endogenous H2S
generating enzymes have been identified in mammals. Des-
ulphydration of cysteine is the major source of H2S in
mammals and is catalysed by the trans-sulphuration pathway
enzymes, cystathionine β-synthase (CBS), cystathionine
γ-lyase (CSE) and 3-mercaptopyruvate sulphurtransferase
(3-MST). Cystathionine can be converted by CSE to form H2S.
CBS can form cystathionine from serine and homocysteine,
and additionally can form H2S from cysteine. Cysteine, along
with α-ketoglutarate, is converted into 3-mercaptopyruvate
(3MP) by cysteine aminotransferase. 3MP can then be broken
down by 3-MST to form H2S (Predmore et al., 2012). In the
heart, there is little CBS, whereas CSE is plentiful (Chen et al.,
1999; Geng et al., 2004). The observation that the heart con-
tains significant levels of H2S synthesizing enzyme suggests
that it represents an important source of H2S generation
(Szabo et al., 2011). Intracellular H2S is apparently rapidly
oxidized to S2O32− (thiosulphate) by mitochondria with the
subsequent conversion into SO32− and SO42−. SO32− and SO42−
are also produced upon oxidation of H2S by activated neutro-
phils, where SO32− induced the respiratory burst leading to
further H2S oxidation and loss by several endogenous oxidant
species elevated during disease processes, such as NO, super-
oxide, hypochlorite, H2O2 and ONOO−. Furthermore, SO32−
readily undergoes hepatic metabolism forming SO42− (see
Whiteman et al., 2011). The physiological functions of H2S
are mediated by different molecular targets, such as different
ion channels and signalling proteins. Alternations of H2S
metabolism lead to an array of pathological disturbances in
the form of hypertension, atherosclerosis, heart failure, dia-
betes, cirrhosis, inflammation, sepsis, neurodegenerative
disease, erectile dysfunction and asthma (see Lynn and
Austin, 2010; Wang, 2012).
Endogenous CO is generated from endogenous sources
and is now established as an important, biologically active
molecule. CO is generated by haem oxygenases (HO-1 and
HO-2) as a result of the degradation of haem. The catalysed
reaction results in the formation of ferrous iron (Fe2+), CO and
biliverdin, which is rapidly reduced to bilirubin, a reaction
that requires O2 and NADPH. This reaction is biologically
important as it is crucial to iron and bile metabolism, and also
generates a highly effective antioxidant, bilirubin. Both atrial
and ventricular cardiac myocytes express HO-1 and HO-2,
and as in many other tissues, HO-1 expression is inducible (it
is also known as heat shock protein 32), whereas HO-2
expression is constitutive (for a review, see Peers and Steele,
2012).
CO is capable of modulating a number of signalling path-
ways. These pathways include those involving NO/GC, ROS
and MAPKs. The relevant biosynthetic enzyme, HO, has a
central role in cellular antioxidant defence and vascular pro-
tection, and it may mediate many of the actions of drugs used
in cardiovascular therapy (Muchova et al., 2007). Cardiovas-
cular tissues express HO, which metabolizes haem to form
CO. Up-regulation of HO-1 occurs in the heart after stress
such as I/R and provides cardioprotection; most evidence
indicates that CO is responsible for most of these beneficial
effects (Johnson et al., 2004; Peers and Steele, 2012), as it
exerts anti-apoptotic and cytoprotective effects (Stein et al.,
2012). CO also has antihypertensive and anti-inflammatory
effects (Muchova et al., 2007).
Besides the NO, H2S and CO, there are other gasotrans-
mitters, such as hydrogen, methane, as well as some noble
gases (He, Xe) that also exert cardioprotective effects. Inhala-
tion of hydrogen gas has been shown to limit infarct size
following I/R injury in rat and in canine hearts via opening of
mitochondrial KATP channels followed by inhibition of mito-
chondria permeability transition pore opening (mPTP)
(Yoshida et al., 2012). The noble gas helium (He) is capable of
inducing early and late PC at concentrations of 70 and 30%,
respectively, by prevention of mPTP opening (Pagel et al.,
2007; Huhn et al., 2009). However, the majority of research
conducted to date has examined the cardioprotective effects
of xenon because this noble gas exerts anaesthetic and anal-
gesic effects under normal (as opposed to hyperbaric) atmos-
pheric pressure conditions. A growing body of experimental
evidence indicates that brief, intermittent exposure to this
noble gas before prolonged coronary artery occlusion and
reperfusion protects against irreversible ischaemic injury (see
Pagel, 2010). In this review, we will focus on NO, H2S and CO.
BJPGasotransmitters and cardioprotection
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The purpose of the present review is to summarize recent
findings on the role of the gasotransmitters NO, H2S and CO
in myocardial I/R injury and cardioprotection and to high-
light future perspectives in developing modulators of these
gasotransmitters for cardioprotection.
NO in I/R injury and cardioprotection
The role of NO and peroxynitrite in I/R injury and in cardio-
protection by PC has been extensively reviewed earlier
(Ferdinandy and Schulz, 2003; Schulz et al., 2004; Cohen
et al., 2006; Ferdinandy, 2006; Jones and Bolli, 2006). There-
fore, here we focus on more recent studies and especially the
involvement of NO signalling in PostC and RC that has not
yet been reviewed.
Endogenous NO in I/R injury and
preconditioning
Since the discovery of NO, abundant data have been accu-
mulating on the role of NO in the signalling mechanism of
I/R injury and cardioprotection by PC in the heart. In brief,
NO is a well-known cardioprotective molecule via the cGMP/
PKG pathway, as a key molecule in the RISK (reperfusion
injury salvage kinase) and SAFE (survivor activating
factor enhancement) cardioprotective pathways, and via
S-nitrosylation of proteins including, for example, the sarco/
endoplasmic reticulum Ca2+-ATPase and several mitochon-
drial proteins (see Burley et al., 2007; Heusch et al., 2008; Sun
and Murphy, 2010; Murphy et al., 2012; Schulz and
Ferdinandy, 2013). During ischaemia, there is an accumula-
tion of tissue NO from both enzymic and non-enzymic
sources; therefore, upon reperfusion, due to a burst of ROS
release, NO is converted into peroxynitrite, thereby contrib-
uting to reperfusion injury. High doses of NOS inhibitors
given before ischaemia decrease I/R injury via decreasing
peroxynitrite formation. On the contrary, PC by brief periods
of I/R cycles leads to moderate increase in NO and peroxyni-
trite formation, which, in turn, leads to a decrease in NO and
peroxynitrite formation after a prolonged I/R, thereby
leading to cardioprotection (Ferdinandy and Schulz, 2003;
Schulz et al., 2004; Ferdinandy, 2006). Indeed, in the presence
of NOS inhibitors or in NO-deficient states, such as hyperlipi-
daemia, diabetes and sensory neuropathy, the cardioprotec-
tion afforded by PC is lost, showing that intact basal NO
synthesis in the heart is necessary to achieve cardioprotection
by PC (see Ferdinandy et al., 2007).
The role of NO in late PC is still not precisely known.
Although increased iNOS expression seems to be an impor-
tant element of cardioprotection by late PC (for reviews, see
Ferdinandy and Schulz, 2003; Jones and Bolli, 2006), it has
been shown that late PC-induced iNOS expression does not
lead to increased NO formation in the rat heart (Bencsik et al.,
2010).
In summary, although NO is an important element in
triggering the signal of PC as well as in several cardioprotec-
tive signalling cascades, excess NO accumulation during
ischaemia contributes to reperfusion injury via nitrative stress
by peroxynitrite.
Endogenous NO in postconditioning
Endogenous NO and peroxynitrite have been shown by
several studies to be involved in the mechanism of ischaemic
PostC. In mouse isolated hearts, ischaemic PostC reduced the
infarct size, the effect being blocked by treatment with the
eNOS inhibitor L-NAME (Tong et al., 2014). In rat hearts,
ischaemic PostC increased cardiac peroxynitrite formation;
however, PostC in the presence of the peroxynitrite decom-
position catalyst 5,10,15,20-tetrakis(4-sulphonatophenyl)
porphyrinato iron (FeTPPS) inhibited the infarct size, reduc-
ing the effect of PostC (Kupai et al., 2009). Similarly, intrave-
nous FeTPPS, given before PostC, abolished its beneficial
effect, as shown in another study (Li et al., 2013). This study
suggests that interaction of NO and ROS at early stages
of reperfusion contributes to the triggering signal for
cardioprotection by PostC. However, at late stages of
reperfusion, ischaemic PostC reduced post-ischaemic myocar-
dial iNOS activity and nitrotyrosine formation and reduces
myocardial infarct size in rats and humans as well. Adminis-
tration of the iNOS inhibitor 1400W mimicked, whereas
3-morpholinosydnonimine abolished the effects of PostC
(Fan et al., 2011). Thus, an increased NO-peroxynitrite
signalling is important in triggering cardioprotection by
PostC, which, in turn, reduces peroxynitrite-induced nitro-
oxidative stress at late reperfusion, thereby contributing to
cardioprotection.
In mouse hearts, ischaemic PostC reduces the infarct size
independent of whether or not PKG is present, as shown in
PKG knockout mice. Similarly, mitochondria-targeted
S-nitrosothiols (MitoSNO), which accumulate within the
mitochondria where they generate NO and carry out the
S-nitrosation of thiol proteins, also reduce infarct size when
given during reperfusion, independent of the presence of
PKG (Methner et al., 2013). MitoSNO protects mice hearts in
vivo against I/R injury through S-nitrosation of mitochondrial
complex I, which is the entry point for electrons from NADH
into the respiratory chain. Reversible S-nitrosation of
complex I slows down the reactivation of mitochondria
during the crucial first minutes of the reperfusion of ischae-
mic tissue, thereby decreasing ROS production, oxidative
damage and tissue necrosis. Inhibition of complex I is
afforded by the selective S-nitrosation of Cys39 on the ND3
subunit, which becomes susceptible to modification only
after ischaemia. These results indicate that rapid complex I
reactivation contributes to I/R injury (Chouchani et al.,
2013). Apart from the respiratory complexes, ischaemic PostC
causes a 25% or greater increase in S-nitrosylation (SNO) of a
number of proteins, which is blocked by treatment with
L-NAME in parallel with the loss of protection. Furthermore,
77 unique proteins with SNO sites only affected by PostC
have been identified (Tong et al., 2014).
While ischaemic PostC protection involves NO, in rats
treated with nitroglycerin for 3 days to induce vascular
nitrate tolerance that causes systemic nitro-oxidative stress,
ischaemic PostC failed to decrease infarct size. Phosphoryla-
tion of ERK1/2, Akt or eNOS showed no significant differ-
ences in hearts being responsive to PostC or lacking
protection due to nitrate tolerance (Fekete et al., 2013).
In conclusion, it seems that an increased NO-
peroxynitrite signalling is important in triggering cardiopro-
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tection by PostC; however, PostC, in turn, will reduce
peroxynitrite-induced nitro-oxidative stress at late reperfu-
sion, thereby contributing to cardioprotection. The most
important downstream signalling pathway for NO in PostC
likely involves S-nitrosylation of proteins and is independent
of cGMP signalling.
Endogenous NO in remote conditioning
There are limited results available so far, and they are some-
what controversial regarding the role of NO in RC. In an early
study in a rat model of RC, induced by ischaemia of the small
intestine, NOS inhibition by Nω-nitro-L-arginine (L-NNA) did
not affect cardioprotection (Petrishchev et al., 2001). Simi-
larly, in rabbits preconditioned by pulmonary ischaemia, the
NOS inhibitor L-NAME did not affect cardioprotection (Tang
et al., 2014). However, in rats with brief femoral artery
ischaemia-induced myocardial PC, cardioprotection was
mediated by a combination of increased NO synthesis,
opening of mitoKATP channels and increased ROS production
(Shahid et al., 2008). In a rabbit renal ischaemia-induced
remote PC, cardioprotection was associated with a PPAR-
mediated increase in iNOS expression (Lotz et al., 2011).
In rabbits preconditioned by transient limb ischaemia,
interestingly, pre-treatment by the NO donor S-nitroso-N-
acetylpenicillamine abolished cardioprotection (Steensrud
et al., 2010). In a hind limb ischaemia-induced late PC mice
model, cardioprotection was associated with increased iNOS
expression (Li et al., 2004).
In summary, the role of NO in RC is controversial, prob-
ably due to different methods to induce RC. The role of
peroxynitrite in RC has not been studied yet.
Exogenous NO in cardioprotection
As NO is a cytoprotective molecule, NO donor drugs includ-
ing NO gas itself are promising tools for pharmacological
cardioprotection. In this section, NO donor therapies with
potential cardioprotective effect are reviewed.
Organic nitrates. Organic nitrates are the oldest NO donor
compounds. Glyceryl trinitrate (commonly called nitroglyc-
erin) have been used for the prevention and treatment of
ischaemic heart disease for more than 100 years. Organic
nitrates effectively alleviate the severity of myocardial ischae-
mia via their haemodynamic effects, but also contribute to
cardioprotection via a NO-induced activation of KATP chan-
nels in the heart (see Csont and Ferdinandy, 2005). However,
the main limitation of long-term prophylactic nitrate therapy
is the development of vascular nitrate tolerance, which leads
to the attenuation of clinical efficacy (see Csont and
Ferdinandy, 2005; Csont, 2010; Münzel and Gori, 2013). In
preclinical studies, nitrate tolerance aggravated I/R injury
and abolished the cardioprotective effect of PC, possibly
due to increased systemic formation of peroxynitrite (see
Ferdinandy et al., 2007). A human study (Gori et al., 2010)
reported that the endothelial preconditioning effect of a
single dose of nitroglycerin was lost upon a prolonged expo-
sure to nitroglycerin. Nevertheless, the acute administration
of nitrates appears not to interfere with RC in patients under-
going coronary artery bypass graft surgery (Kleinbongard
et al., 2013).
In conclusion, organic nitrates are effective cardioprotec-
tive agents; however, when nitrate tolerance develops, in
addition to the loss of their cardioprotective effect, they may
interfere with endogenous cardioprotective mechanisms via
pathologically increased nitro-oxidative stress.
Nitrite. For a long time, it has been proposed that nitrite is
just an inert metabolite of NO. Over the past years,
however, it has been shown that nitrite can be recycled to
bioactive NO under conditions of hypoxia/ischaemia via
reaction with haemoglobin and other endogenous nitrite
reductases such as myoglobin, neuroglobin, cytoglobin,
xanthine oxidoreductase (XOR), eNOS and some mitochon-
drial enzymes (see Rassaf et al., 2014). Therefore, modifica-
tion of endogenous nitrite levels by exogenous nitrite and
nitrate either from dietary sources or nitrite-containing
preparations, as a therapeutic tool to modify NO signalling
has been intensively investigated (see Rassaf et al., 2014).
The administration of sodium nitrite exerts cytoprotective
effects in myocardial I/R injury (Webb et al., 2004; Dezfulian
et al., 2007; Hendgen-Cotta et al., 2008). Nitrite is reduced
to NO, S-nitrosothiols, N-nitrosamines and iron-nitrosylated
haem proteins during early reperfusion (Rassaf et al., 2007).
The cytoprotective effects of nitrite are independent of
eNOS. Whereas Webb et al. showed that the reduction of
nitrite to NO was XOR-dependent (Webb et al., 2004),
another research group demonstrated that myoglobin is the
main nitrite reductase in the myocardium (Hendgen-Cotta
et al., 2008; 2010a,b; Totzeck et al., 2012a,b), as the reduc-
tion in infarct size following administration of nitrite was
completely abolished in myoglobin knockout mice. Two
distinct mechanisms have been described for the protective
effects of nitrite. In one mechanism, nitrite modifies and
inhibits complex I by post-translational S-nitrosation. This
dampens electron transfer and reduces ROS generation and
ameliorates oxidative inactivation of complexes II–IV and
aconitase. This prevents mPTP opening and cytochrome c
release. The other potential mechanism of nitrite-
induced protection relates to the modification of the mPTP
opening. This plays a critical role in mediating cell
death during I/R injury. Cyclophilin D (Cyp D), which
accelerates mPTP opening, undergoes S-nitrosylation on
Cys203, leading to reduced mPTP opening in mice wild-type
fibroblast but not in Cyp D knockout fibroblasts (Nguyen
et al., 2011).
In conclusion, a low dose of nitrite anion is a promising
cardioprotective agent, at least in part, via its reduction to NO
in the ischaemic heart.
Miscellaneous NO donors. Several pharmacological com-
pounds directly stimulating NO signalling pathways have
been demonstrated to protect the heart against I/R injury
when applied before ischaemia or at reperfusion (see Jones
and Bolli, 2006; Pacher et al., 2007).
NO gas inhalation during coronary occlusion has been
shown to provide infarct size reduction and leads to a
decrease in peroxynitrite formation in rats and mice
(Nagasaka et al., 2008; Neye et al., 2012; Shinbo et al., 2013),
showing that NO inhalation may represent a promising early
intervention in acute myocardial infarction patients. Accord-
ingly, a phase 2 clinical trial investigating the effects of NO
BJPGasotransmitters and cardioprotection
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for inhalation in myocardial infarct size (NOMI trial,
NCT01398384) is ongoing.
Several NO-releasing derivatives of known drugs have
been developed and investigated for cardioprotection.
In mice, a NO-releasing pravastatin (Ncx-6550) dose-
dependently reduced infarct size following —I/R and the dose
required for protection was one-tenth of that of pravastatin
alone (Di Filippo et al., 2010). More interestingly, however,
pravastatin, in contrast to the same dose of simvastatin or
ischaemic PostC, reduced infarct size in hypercholesterolae-
mic rabbits independent of its lipid lowering action, poten-
tially through eNOS activation and attenuation of nitro-
oxidative stress (Andreadou et al., 2012). Nitro-aspirin
(NCX4016) has also been shown to effectively reduce infarct
size in preclinical models (Wallace et al., 2002; Fu et al.,
2007). Nicorandil, a NO-donor and KATP channel opener, has
been shown to reduce the infarct size in rabbit hearts (Argaud
et al., 2009). However, a meta-analysis of available small-scale
clinical trials could not show direct benefit in myocardial
infarction patients from nicorandil treatment, possibly due to
the lack of large clinical trials (Wu et al., 2013).
There are several novel compounds with potential car-
dioprotective properties, whose mechanisms of action
depend upon NO signalling. PostC with isoflurane decreases
infarct size in wild-type mice. Mitochondria isolated from
postconditioned hearts require significantly higher in vitro
calcium loading than did controls to open the mPTP. In
hearts from eNOS knockout mice, isoflurane PostC failed to
alter the infarct size or mPTP opening (Ge et al., 2010). The
mechanism(s) involved in modifying mPTP opening might
involve indirect effects through protein kinases or direct
SNO-protein modifications. Indeed, pharmacological PostC
with diazoxide induced a redox-sensitive phosphorylation/
translocation of Akt, ERK1/2 and glycogen synthase kinase
3β (GSK3β) into the mitochondria and increased mitochon-
drial S-nitrosylated proteins, such as voltage-dependent
anion channels, in rat isolated hearts (Penna et al., 2013).
Moreover, a mitochondria-selective S-nitrosating agent,
MitoSNO, has been shown to reduce the infarct size in mice
(Chouchani et al., 2013). In mouse isolated hearts, netrin-1
PostC reduced the infarct size and this effect is abolished by
the NO scavenger, 2-phenyl-4,4,5,5-tetramethylimidazoline-
1-oxyl 3-oxide (Bouhidel et al., 2014). Apelin-13 was ineffec-
tive in reducing infarct size in rat isolated hearts with pre-
treatment, but when administered after ischaemia, it reduced
infarct size, which was partially blocked by LNNA. Thus,
apelin-13 protects the heart only if given after ischaemia,
and in this protection, NO plays an important role (Rastaldo
et al., 2011).
There is increasing evidence for the formation of the
nitroxyl anion (NO- , which exists as HNO in aqueous solu-
tions) by NOS (Hobbs et al., 1994), lending further support to
the assumption that this redox sibling of NO is involved in
modulation of cardiac function under both normal and
pathological (post-ischaemic) conditions. The infusion of
HNO, generated by the HNO donor Angeli’s salt (sodium
trioxodinitrate, Na2N2O3), prior to I/R exerts protective effects
in rat isolated perfused hearts, a protection that resembles the
phenomenon of ‘early preconditioning’ (Pagliaro et al.,
2003). Furthermore, the vasoprotective effects of the HNO
donor isopropylamine NONOate (IPA/NO) have been main-
tained in hypercholesterolaemia, and thus, HNO donors may
represent future novel treatments for vascular diseases
(Bullen et al., 2011).
In conclusion, NO donor molecules and molecules that
activate cardioprotective NO-dependent signalling pathways
are promising tools for cardioprotection.
Role of endogenous H2S in I/R injury
and cardioprotection
H2S in I/R injury
Endogenous H2S may play a role in the regulation of cardio-
vascular function and inflammatory/immune responses as a
potential endogenous gasotransmitter. Although the heart
expresses all three H2S generating enzymes, most of the work
has focused on the role of CSE-derived H2S. Most of the
studies that investigated the role of endogenous H2S in car-
dioprotection have used DL-propargylglycine (PRG) or cyano-
L-alanine (BCA) as inhibitors for H2S synthesis. It should be
noted that these compounds exhibit selectivity towards CSE,
allowing H2S production to continue through CBS and
3-MST; moreover, they are known to inhibit other pyridoxal
5′-phosphate-dependent enzymes (Asimakopoulou et al.,
2013). In rat isolated hearts, infarct size increased when
endogenous H2S production was inhibited by blocking CSE
with PRG (Bliksoen et al., 2008). In the same experimental
model, exogenous L-cysteine administration limited I/R
injury through a mechanism that appeared to be at least
partially dependent upon H2S synthesis and production was
attenuated by PRG treatment (Elsey et al., 2010). Addition-
ally, the modulation of endogenously produced H2S by
cardiac-specific overexpression of CSE significantly limited
the extent of injury (Elrod et al., 2007). Very recently, it has
been shown that, in mice lacking CSE, myocardial I/R injury
was exacerbated, whereas H2S therapy attenuated I/R injury
(King et al., 2014).
H2S in preconditioning. The endogenous production of H2S is
required for ischaemic PC. H2S production was decreased
when ventricular myocytes were subjected to ischaemia. PC
significantly attenuated the inhibitory effect of ischaemia on
H2S production, proving that endogenous H2S plays an
important role in cardioprotection (Bian et al., 2006). In rat
isolated cardiac myocytes, CSE inhibition, using PRG or BCA,
reversed the cardioprotective effects of ischaemic PC on cell
viability and morphology (Pan et al., 2006). Furthermore,
treatment of cardiac myocytes with either PRG or BCA mark-
edly decreased endogenous H2S production and significantly
attenuated the protective effect of PC (Bian et al., 2006).
In an in vivo rat model of myocardial I/R, NaHS (a donor
of H2S) reduced infarct size, apoptosis, the expression levels of
Fas, FasL and cleaved caspase-3 proteins. In contrast, PRG
showed opposite effects to NaHS (Yao et al., 2012). PRG
administration for 1 week and 2 days after I/R abolished the
decrease of infarct size, compared with the group treated with
NaHS, whereas a marked reduction of the infarct size and
up-regulation of survivin was observed in the group treated
with NaHS (Zhuo et al., 2009).
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H2S in postconditioning. The endogenous production of H2S is
also required for ischaemic PostC. Indeed, ischaemic PostC
stimulated the activity of H2S-generating enzymes in the early
phase of reperfusion (Yong et al., 2008), and PRG partly
attenuated the cardioprotective effect of PostC (Huang et al.,
2012). Pre-treatment with PRG, prior to global ischaemia,
attenuated the reduction in infarct size by PostC (Yong et al.,
2008). Additionally, the modulation of endogenously pro-
duced H2S by cardiac-specific overexpression of CSE signifi-
cantly limited the extent of injury (Elrod et al., 2007). The
role of H2S in RC has not yet been determined.
In conclusion, all the results described above demonstrate
that H2S may be of significant importance in the mechanism
of cytoprotection during evolving myocardial infarction and
that the modulation of endogenous production may be of
clinical benefit in myocardial ischaemia. The beneficial
effects of endogenous H2S in I/R injury, in PC and PostC are
summarized in Table 1.
Cardioprotection by exogenous
H2S administration
H2S donors. By using exogenous H2S therapy, the amount of
injury is reduced in cardiomyocytes, in isolated ex vivo and in
in vivo hearts of various models of I/R injury. The pharmaco-
logical modulation of H2S is becoming a challenging field of
research in drug discovery. The administration of gaseous H2S
is greatly limited by the difficulty to ensure an accurate
control of dose and the risk of overdose (with serious conse-
quences of H2S toxicity). For the above reasons, the use of
H2S-releasing compounds seems to be the most convenient
and satisfactory strategy (see Martelli et al., 2012). NaHS is the
prototypical example of a H2S-generating agent, is a rapid H2S
donor and is widely used for experimental purposes. Ideal H2S
donors for therapeutic purposes should generate H2S with
slow releasing rates. This pharmacological feature seems to be
exhibited by some natural derivatives. Indeed, the beneficial
effects of garlic (Allium sativum L.) on cardiovascular func-
tions have been well recognized for a long time. Alliin is a
sulphur amino acid that is abundantly present in garlic and is
converted to diallyl thiosulphinate (also known as allicin),
which, in turn, rapidly decomposes to more stable organo-
sulphur compounds, such as diallyl sulphide, ajoene and
diallyl polysulphides (diallyl disulphide and trisulphide).
Diallyl disulphide and trisulphide diallyl disulphide and tri-
sulphide are true H2S donors and release H2S with a relatively
slow mechanism, which requires the cooperation of endog-
enous thiols (such as reduced glutathione) (Benavides et al.,
2007). Besides the above-mentioned organic polysulphides
Table 1
The beneficial effects of endogenous H2S in ischaemia/reperfusion injury, in PC and PostC
Experimental model Effect of H2S Proposed mechanism(s) Reference
Rat isolated hearts L-cysteine reduced I/R in a
dose-dependent manner and PRG
reversed this protection
L-cysteine produced a threefold
elevation of endogenous left
ventricular H2S concentration, and it
was attenuated by PRG treatment
Elsey et al. (2010)
Rat cardiomyocytes; rat
isolated hearts
PRG or BCA markedly decreased
endogenous H2S production and
significantly attenuated the protective
effect of PC
KATP and PKC activation Bian et al. (2006)
Rat isolated ventricular
myocytes
PRG or BCA reversed the
cardioprotective effects of myocardial
PC on cell viability, morphology and
electrically induced [Ca2+]i
Activation of sarcolemmal KATP channels
and/or provoking NO release
Pan et al. (2006)
Rat isolated hearts PRG increased I/R Decreased phosphorylation of Akt with
PAG
Bliksoen et al. (2008)
Rat isolated hearts Loss of PostC protection after PRG
administration
Peak of H2S production in the early
reperfusion state
Huang et al. (2012)
Rat isolated hearts PostC significantly stimulated H2S
synthesis enzyme activity during the
early period of reperfusion.
Administration of PRG abolished the
protection of the PostC.
Activation of the pro-survival PKC-e and
PKC-a
Yong et al. (2008)
In vivo (rats) NaHS significantly reduced the
myocardial infarct size. PRG
administration showed opposite
effects to NaHS. PRG increased I/R.
Reduced expression levels of Fas, FasL
and cleaved caspase-3 proteins
Yao et al. (2012)
In vivo (rats) PRG increased I/R Up-regulation of survivin Zhuo et al. (2009)
In vivo (mice overexpressing
CSE in heart)
Reduction of reperfusion injury Partial inhibition of mitochondrial
respiration
Elrod et al. (2007)
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of natural origin, some synthetic H2S-releasing agents
described. Among them, the phosphinodithioate derivative
GYY4137 (morpholin-4-ium 4-methoxyphenyl-morpholino-
phosphinodithioate) represents an attractive example (Li
et al., 2008). Several concepts that have been previously used
by medicinal chemistry for improving well-known drugs
through the development of ‘NO-hybrids’ are presently
being translated to the design of ‘H2S hybrids’. This general
concept has been applied also to the design of H2S-releasing
non-steroidal anti-inflammatory drugs (NSAIDs), obtained
through the conjugation of the ‘parent’ NSAIDs with a dithi-
olethione moiety [5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-
thione] (HPDTT), which is currently the most widely used
H2S-releasing moiety for synthesizing pharmacological
hybrids (Li et al., 2007; Sparatore et al., 2009). Another class
of H2S donors is thioamino acids that release H2S upon reac-
tion with bicarbonate at a rate that is faster than GYY4137,
yet appreciably slower than Na2S or NaSH (Zhou et al., 2012).
Detailed reviews of H2S donors (Martelli et al., 2012;
Whiteman et al., 2011; Kashfi and Olson 2013) and an excel-
lent methodological review on how to measure H2S (Nagy
et al., 2014) are available.
In conclusion, exogenous compounds, which behave as
sources of H2S, are viewed as powerful tools for basic studies
and innovative pharmacotherapeutic agents for a variety of
cardiovascular diseases.
In vitro studies. NaHS caused cardioprotection, in terms of
cell viability and electrically induced calcium [Ca2+]i tran-
sients (Pan et al., 2006). In cultured cardiomyocytes, NaHS
showed concentration-dependent inhibitory effects of apop-
tosis induced by hypoxia/reoxygenation (Yao et al., 2010).
Furthermore, NaHS significantly increased cell viability, per-
centage of rod-shaped cells and myocyte contractility (Hu
et al., 2008b). A rapid, time-dependent phosphorylation of
JNK was observed in cultured rat neonatal cardiomyocytes,
whereas NaHS inhibited this early phosphorylation of JNK,
concluding that the early JNK inhibition during reperfusion
is associated with H2S-mediated protection against cardio-
myocyte apoptosis (Shi et al., 2009).
Perfusion with NaHS significantly improved post-
ischaemic contractile recovery (Hu et al., 2011), decreased
myocardial infarct size and improved left ventricular (LV)
contractile function (Bian et al., 2006; Bliksoen et al., 2008;
Hu et al., 2008a). Treatment of rat isolated hearts with NaHS,
10 min prior to the onset of coronary occlusion, resulted in a
concentration-dependent limitation of infarct size (Johansen
et al., 2006).
The new H2S-releasing derivative of diclofenac,
S-diclofenac (2-[(2,6-dichlorophenyl)amino]benzene acetic
acid 4-(3H-1,2-dithiole-3-thione-5-yl)-phenyl ester), had
marked anti-ischaemic activity (Rossoni et al., 2008). Further-
more, pharmacological PC with allitridum resulted in signifi-
cantly smaller infarcts than in control hearts (Zhang et al.,
2001).
The mechanisms accounting for H2S-induced cardiopro-
tective activities in cardiomyocytes include prevention of
leukocyte adherence (Zanardo et al., 2006), inhibition of
excessive production of NO and of NF-κB in macrophages
(Oh et al., 2006), activation of the sarcolemmal KATP channels
(Pan et al., 2006), deactivation of GSK-3β and decreased trans-
location of Bax, caspase-3 activation and inhibition of mPTP
opening (Yao et al., 2010). Moreover, H2S produced delayed
cardioprotection via KATP/PKC-dependent induction of
COX-2 expression and via NO-induced COX-2 activation (Hu
et al., 2008b), inhibition of oxidative stress and activation of
superoxide dismutase (SOD) (Sun et al., 2012). The mecha-
nism accounting for H2S cardioprotective activities when it is
administered prior to sustained ischaemia in isolated hearts
involves a PI3K/Akt/PKG-dependent mechanism (Hu et al.,
2011), contribution of KATP/PKC/ERK1/2 and PI3K/Akt path-
ways (Hu et al., 2008a), and expression of heat shock protein
72 (Bliksoen et al., 2008).
However there is controversy over the involvement of
mitoKATP channels in the cardioprotective activity of H2S.
Bian et al. (2006) showed that blockade of mitoKATP channels
with 5-hydroxydecanoic acid had no effect on the cardiopro-
tection afforded by exogenous H2S, suggesting that contrary
to the mechanism of classic PC, mitoKATP channels most prob-
ably do not play a major role in the cardioprotection afforded
by H2S. However, other studies (Johansen et al., 2006; Rossoni
et al., 2008) have shown that pre-treatment with the KATP
channel blockers glibenclamide or 5-hydroxydecanoate abol-
ished the infarct-limiting effect of NaHS.
Concerning the effect of H2S on PostC, studies in isolated
hearts have shown that treatment with NaHS at the onset of
reperfusion results in a reduction of infarct size (Luan et al.,
2012), a cardioprotective effect similar to that of PostC (Ji
et al., 2008). In another study, treatment with NaHS also
resulted in a significant improvement in LV function and
reduction of arrhythmia scores (Zhang et al., 2007). Pharma-
cological PostC with six cycles of a 10 s infusion of NaHS or
2 min continuous NaHS infusion reduced myocardial infarct
size in rat isolated hearts (Yong et al., 2008).
In isolated hearts, it seems that mitoKATP channel opening
is involved in the H2S-induced PostC (Zhang et al., 2007; Ji
et al., 2008). H2S PostC confers the protective effects against
I/R injury also through the activation of Akt, PKC and eNOS
pathways (Yong et al., 2008). Moreover, recently, it has been
shown that H2S PostC protected rat isolated hearts via the
activation of the JAK2/STAT3 signalling pathway (Luan et al.,
2012).
In conclusion, further studies are required to elucidate the
potential role of H2S as a cytoprotective mediator against
myocardial I/R injury, the mechanisms regulating its genera-
tion and the nature of its interaction with protein targets
such as the KATP channels.
In vivo studies. NaHS administration before sustained
ischaemia resulted in a remarkable reduction of the infarct
size (Zhuo et al., 2009) and significantly reduced cell apopto-
sis (Sivarajah et al., 2009; Yao et al., 2012). Furthermore, a
single bolus of NaHS administered 24 h before myocardial
infarction produced a strong infarct-limiting effect and a
time-course study demonstrated that the protection lasted for
at least 3 days after the PC stimulus (Pan et al., 2009). When
H2S was administered to mice before myocardial ischaemia, it
provided profound protection against ischaemic injury
(Calvert et al., 2009).
In the above studies, the mechanism of the cardioprotec-
tive effect of NaHS in the in vivo models was focused on
anti-apoptotic and anti-inflammatory effects. H2S reduced
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calcineurin activity and the expression levels of Fas, FasL and
cleaved caspase-3 proteins (Yao et al., 2012). More specifically,
during the early PC period, H2S increased the nuclear locali-
zation of Nrf2, a transcription factor that regulates the gene
expression of a number of antioxidants and increased the
phosphorylation of PKCε and STAT-3. During the late PC
period, H2S increased the expression of antioxidants (HO-1
and thioredoxin 1), of heat shock proteins 90 and 70, Bcl-2,
Bcl-xL and COX-2, and also inactivated the pro-apoptogen
Bad (Calvert et al., 2009). Furthermore, it attenuated the
increase in caspase 9 activity, the decrease in the expression
of Bcl-2, the phosphorylation of p38 MAPK and JNK, the
polymorphonuclear leukocyte accumulation, myeloperoxi-
dase activity, malondialdehyde levels, and nitrotyrosine
staining in rat hearts, subjected to regional myocardial I/R.
The cardioprotective effects of NaHS were abolished by
5-hydroxydeconoate; thus, it seems that the anti-apoptotic
effect of NaHS may partially be related to the opening of the
mitoKATP channels (Sivarajah et al., 2009). PC with H2S also
produced strong late cardioprotection through a PKC-
dependent mechanism (Pan et al., 2009). Studies to explore
the molecular mechanism of H2S-induced cardioprotection in
mice showed that administration of NaHS increased signifi-
cantly serum as well as myocardial NO levels without any
sign of myocardial injury. Typical characteristics of
isoprenaline-induced myocardial injury were abolished by
NaHS administration as shown by reduction in elevated thio-
barbituric acid reactive substances and normalization of GSH,
glutathione peroxidase, SOD and catalase activity. Further-
more, a decrease in TNF-α expression and an improvement of
myocardial architecture was also observed and the inhibition
of NOS abolished the H2S-induced cardioprotection in mice
(Sojitra et al., 2012).
S-allylcysteine (SAC), which is an organosulphur-
containing compound derived from garlic, mediated cardio-
protection via a H2S-related pathway in rats and significantly
lowered mortality and reduced infarct size, whereas protein
expression studies revealed that SAC up-regulated CSE expres-
sion (Chuah et al., 2007).
In anaesthetized and mechanically ventilated pigs sub-
jected to ischaemia/reperfusion, Na2S reduced the heart rate
and the cardiac output without affecting stroke volume
(Simon et al., 2008). In animals with co-morbidities, admin-
istration of Na2S beginning 24 h or 7 days before myocardial
ischaemia significantly decreased infarct size in db/db diabetic
mice. This result indicated that diabetes did not alter the
ability of H2S to increase the nuclear localization of Nrf2, but
it impaired aspects of Nrf2 signalling. Exogenous administra-
tion of Na2S attenuated myocardial ischaemia–reperfusion
injury in db/db mice, suggesting the potential therapeutic
effects of H2S in treating lethal arrhythmias and heart attack
in the setting of type 2 diabetes (Peake et al., 2013).
However, few studies so far have investigated the cardio-
protective effect of exogenous administered H2S during rep-
erfusion. The delivery of H2S at the time of reperfusion can
limit infarct size and preserve LV function in mice (Elrod
et al., 2007). In an experimental model of shock and
ischaemia/reperfusion, haemorrhage-induced lactic acidosis
and ex vivo vascular hyporeactivity, were attenuated by
NaHS (Issa et al., 2013). Post-therapeutic sulphide provided
protection following I/R injury in pigs, improved myocardial
function, reduced infarct size and improved coronary micro-
vascular reactivity (Sodha et al., 2009). The effects of different
regimens of parenteral H2S administration on myocardium
during I/R were investigated in Yorkshire pigs. Continuous,
but not bolus H2S infusion markedly reduced myocardial
infarct size and improved regional LV function, as well
as endothelium-dependent and endothelium-independent
microvascular reactivity (Osipov et al., 2009).
The cytoprotection observed in these studies was mainly
associated with an inhibition of myocardial inflammation
and a preservation of both mitochondrial structure and func-
tion after I/R injury (Elrod et al., 2007). NaHS protected
against the effects of haemorrhage-induced I/R by acting
primarily through a decrease in both pro-inflammatory
cytokines and iNOS expression and an up-regulation of the
Akt/eNOS pathway (Issa et al., 2013). Exogenous sulphide
may have therapeutic utility in clinical settings in which
I/R injury is encountered potentially through its anti-
inflammatory activities (Sodha et al., 2009). The beneficial
effects of exogenous H2S administration in cardioprotection
are shown in Table 2.
In conclusion, there are only few studies concerning the
cardioprotective effects of exogenous administration of H2S
in models of I/R in vivo. The intracellular signalling pathways
underlying the protection are completely unknown. Further-
more, there is no study of the role(s) of H2S in triggering
PostC in vivo.
Human studies. It has been suggested that modulating sys-
temic H2S production may represent a viable approach for the
treatment of vascular disease. In one study comparing
patients with coronary heart disease (CHD) with angiographi-
cally normal subjects, the number of affected coronary vessels
correlated with decreased plasma levels of H2S. More specifi-
cally, plasma levels of H2S were significantly lower in CHD
patients with coronary artery occlusion than in patients with
simple stenosis and were also lower in hypertensive patients
than normotensive ones (Jiang et al., 2005).
A clinical study has been performed in order to evaluate
the effectiveness of allicor (garlic powder tablets) treatment in
primary CHD prevention and its effects on the estimates of
multifunctional cardiovascular risk. A 12 month treatment
with allicor resulted in the significant decrease of cardiovas-
cular risk by 1.5-fold in men and by 1.3-fold in women, and
the main effect that played a role in cardiovascular risk reduc-
tion was the decrease in low-density lipoprotein cholesterol
(Sobenin et al., 2010). The effect of 6 weeks of administration
of garlic oil was observed on cardiac performance and exer-
cise tolerance in 30 patients of CHD. Garlic significantly
reduced heart rate at peak exercise and also reduced the
workload upon the heart, resulting in better exercise toler-
ance as compared with the initial test (Verma et al., 2005).
In conclusion, there are no clinical studies so far to
confirm the cardioprotective role of H2S in humans.
Role of endogenous CO in I/R injury
and cardioprotection
The effect of severe hypoxia and reoxygenation on HO-1
expression has been investigated in cardiomyocytes and the
potential protective role of HO-1 and its product bilirubin
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Table 2
The beneficial effects of exogenous administered H2S in ischaemia/reperfusion injury, in PC and PostC
Experimental model Effect of H2S Proposed mechanism(s) Reference
Rat isolated ventricular myocytes
(NaHS)
Cardioprotection in terms of cell
viability, morphology and electrically
induced [Ca2+]i
Activation of sarcolemmal KATP channels
and/or provoking NO release
Pan et al. (2006)
Cardiomyocytes (NaHS) Reduction of apoptosis Phosphorylation of GSK-3β (Ser9) and
subsequent inhibition of mPTP opening
Yao et al. (2010)
Isolated cardiac myocytes (NaHS) Increased cell viability, percentage of
rod-shaped cells, and myocyte
contractility
Delayed cardioprotection via
KATP/PKC-dependent induction of COX-2
expression and via NO-induced COX-2
activation
Hu et al. (2008b)
Primary cultured rat neonatal
cardiomyocytes (NaHS)
Decreased the number of apoptotic
cells, lowered cytochrome c release
Inhibition of the early phosphorylation of
JNK, enhanced Bcl-2 expression
Shi et al. (2009)
Rat isolated hearts PC (NaHS) Improved post-ischaemic contractile
function
Suppression of NHE-1 activity involving a
PI3K/Akt/PKG-dependent mechanism
Hu et al. (2011)
Rat isolated hearts PC (NaHS) Decreased myocardial infarct size and
improved heart contractile function
KATP/PKC/ERK1/2 and PI3K/Akt pathways Hu et al. (2008a)
Rat isolated hearts PC (NaHS) Reduction of infarct size Activation of PKC and sarcKATP. No
involvement of mitoKATP.
Bian et al. (2006)
Rat isolated hearts PC (NaHS) Dose-dependent reduction of infarct size Involvement of KATP channels. Johansen et al. (2006)
Perfused rat hearts; NaHS was
added to the perfusate during
stabilization and throughout the
experiment
Non-significant decrease in infarct size Expression of heat shock protein 72 Bliksoen et al. (2008)
Rabbit isolated heart; H2S-releasing
derivative of diclofenac
Marked anti-ischaemic activity Increased GSH formation leading to
activation of KATP channels
Rossoni et al. (2008)
Rabbit isolated heart; allitridum PC Decrease infarct size Blocked by administration of Poly B, an
inhibitor of PKC, implying that PKC has
an important role in PC
Zhang et al. (2001)
Rat isolated hearts NaHS-PostC Reduction of I/R. Reduction of CK. KATP channels involvement Ji et al. (2008)
Isolated hearts NaHS-PostC Significant improvement in heart
function and arrhythmia scores
H2S increases the open probability of KATP in
cardiac myocytes
Zhang et al. (2007)
Isolated hearts NaHS-PostC Reduction of infarct size Activation of the JAK2/STAT3 signalling
pathway
Luan et al. (2012)
Isolated hearts NaHS PostC Reduction of infarct size Activation of AKT, PKC, eNOS Yong et al. (2008)
In vivo (mice) NaHS PC Reduction of infarct size, decrease of
troponin-I
Decrease of oxidative stress, increase Nfr2,
PKCε, STAT-3, HO-1, Trx1, HSP90,
HSP70, Bcl-2, Bcl-xL, COX-2 and
decrease of Bad
Calvert et al. (2009)
In vivo (rats) NaHS PC Reduction of infarct size Up-regulation of survivin Zhuo et al. (2009)
In vivo (rats) NaHS PC Reduction of infarct size Reduction of calcineurin, Fas, Fas-L,
caspase-3 and increase of ARC
Yao et al. (2012)
In vivo (rats) NaHS PC Reduction of infarct size PKC-dependent mechanism Pan et al. (2009)
In vivo (rats) NaHS PC Reduction of infarct size Decrease in caspase-9, increase of Bcl-2,
mitoKATP opening and increased
phosphorylation of p38
Sivarajah et al. (2009)
In vivo rats S-allylcysteine (SAC) PC Reduction of infarct size SAC up-regulated CSE expression Chuah et al. (2007)
In vivo (pigs) Na2S PC Reduction of infarct size Lower lactate, improvement in
noradrenaline response. No change in
oxidative stress.
Simon et al. (2008)
In vivo (mice) NaHS-PostC Dose dependent reduction of I/R. Anti-inflammatory properties, preservation
of mitochondrial function
Elrod et al. (2007)
In vivo (rat) model of
haemorrhage-induced I/R NaHS
PostC
Shock and I/R induced a decrease in
MAP, lactic acidosis and ex vivo
vascular hyporeactivity, which were
attenuated by NaHS
Decrease in both pro-inflammatory
cytokines and iNOS expression and an
up-regulation of the Akt/eNOS pathway
Issa et al. (2013)
In vivo (pigs) NaHS-PostC Reduction of infarct size Anti-inflammatory effects Sodha et al. (2009)
In vivo (pigs) NaHS-PostC Reduction of infarct size Markers of apoptosis and autophagy
anti-apoptotic effects
Osipov et al. (2009)
db/db diabetic mice (Na2S) PC Decreased myocardial injury Impair aspects of Nrf2 signalling Peake et al. (2013)
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against reoxygenation damage was assessed. Hypoxia caused
a time-dependent increase in both HO-1 expression and HO
activity, which gradually declined during reoxygenation
which produced marked injury. However, incubation with
haemin or bilirubin during hypoxia considerably reduced the
damage that was developed during reoxygenation. Genera-
tion of ROS was enhanced after hypoxia, whereas haemin
and bilirubin attenuated this effect, indicating that the HO-1-
bilirubin pathway can effectively defend hypoxic cardiomyo-
cytes against reoxygenation injury and highlight the
importance of haem availability in the cytoprotective action
afforded by HO-1 (Foresti et al., 2001). Additionally, the car-
dioprotection obtained by gene delivery of the hypoxia-
inducible factor, HIF-1α, depended upon the downstream
factor HO-1. HIF-1α and HO-1 provided protection against
H2O2-induced damage in HL-1 cells. Remote gene delivery of
HIF-1α afforded cardioprotective effects, which were depend-
ent upon HO activity, indicating that downstream to HO-1,
bilirubin and CO may be organ effectors (Czibik et al., 2009).
Moreover, HO-1-deficient mice develop right ventricular
infarction after chronic hypoxia exposure and are more sus-
ceptible to I/R injury (Yet et al., 1999; Yoshida et al., 2001)
and HO-1 overexpression protects the myocardium from I/R
injury (Yet et al., 2001).
Johnson et al. tested the hypothesis that cardiac HO-1
expression is increased in Dahl salt-sensitive (SD) rats with
salt-induced hypertension: the rats were placed on a high- or
low-salt diet for 4 weeks and cardiac HO isoform expression
were determined in isolated paced Langendorff hearts. Coro-
nary arterial HO-1 immunostaining was enhanced in high-
salt rats and suggested that coronary HO-1 expression is
increased to promote enhanced coronary vasodilatation in
salt-induced hypertension (Johnson et al., 2004).
One target of CO appeared to be the L-type Ca2+ channel.
CO directly inhibited wild-type rat cardiomyocyte L-type Ca2+
currents and the recombinant α1C subunit of the human
cardiac L-type Ca2+ channel (Scragg et al., 2008). It also inhib-
ited recombinant and native forms of this cardiac channel via
mitochondria-derived ROS, actions likely to contribute to the
protective effects of CO (Peers and Steele, 2012).
The interaction between the CBS/H2S and HO-1/CO
systems during myocardial I/R was also investigated in SD rats
with hydroxylamine, a CBS inhibitor and zinc protoporphy-
rin (a HO-1 inhibitor). The H2S, CO, GSH and SOD levels were
decreased, the MDA level increased and the HO-1-mRNA and
CBS-mRNA expression levels decreased, compared those in
with rats subjected to I/R only, suggesting that both CBS/H2S
and HO-1/CO systems play a protective role in myocardial I/R
and they interact with each other (Zhu et al., 2008).
In conclusion, although the endogenous production of
CO is required for ischaemic PC, the role of CO in PostC and
RC has not been investigated yet.
Cardioprotection by exogenous administration
of CO
CO donors. Several approaches have been used to investigate
the therapeutic potential of CO, ranging from direct inhala-
tion of CO gas to the use of prodrugs which then generate CO
upon metabolism. A novel approach involves the use of spe-
cific CO carriers, which will release measurable, controllable
and effective amounts of CO into biological systems. Transi-
tional metal carbonyls based on iron, manganese or ruthe-
nium have recently been developed as CO-releasing
molecules (CORMs) that, under appropriate conditions, will
release CO. The problem of low solubility of typical metal
carbonyls has prompted the search for more biocompatible
metal carbonyl complexes bearing amino acids (and their
derivatives) as auxiliary ligands. The facial tricarbonyl fac-
[RuCl(glycinate)(CO)3], often referred to as CORM-3, is the
prototypical water-soluble CORM in this area (Chatterjee,
2004; Johnson et al., 2007). Details of CO donors (Romão
et al. 2012;, Zobi, 2013; Gonzales and Mascharak, 2014) and
an excellent methodological review on measurement tech-
niques of CO (Motterlini and Otterbein, 2010) are available.
Such molecules confer cardioprotection both in ex vivo and in
vivo experiments.
In conclusion, CORMs are an emerging class of pharma-
ceutical compounds that can be used in general consensus
that the therapeutic effects elicited by these molecules may be
directly ascribed to the biological function of the released
CO.
In vitro studies. Pre-treatment with CO prevented apoptosis
in cardioblastic H9c2 cells subjected to I/R. Reperfusion fol-
lowing brief periods of ischaemia induced cytochrome c
release, activation of caspase-9 and caspase-3, and apoptotic
nuclear condensation. Pre-treatment with CO or with the
caspase-9 inhibitor (Z-LEHD-FMK) attenuated these apoptotic
changes. Furthermore, I/R increased the phosphorylation of
Akt after CO pretreatment, whereas the specific Akt inhibitor
API-2 blunted the anti-apoptotic effect of CO, suggesting that
CO induces mitochondrial generation of O2•−, which is then
converted by SOD to H2O2, and the subsequent Akt activation
by H2O2 attenuates apoptosis during —I/R (Kondo-Nakamura
et al., 2010).
Increased cardiac expression of the chemokine CXCL12
(SDF-1α) promoted neovascularization and myocardial repair
after ischaemic injury through recruiting stem cells and
reducing cardiomyocyte death. CO gas and a CO-releasing
compound, tricarbonyldichlororuthenium (II) dimer, dose-
dependently induced CXCL12 expression in primary neona-
tal cardiomyocytes and H9C2 cardiomyoblasts. CO treatment
enhanced neovascularization in the myocardium in the peri-
infarct region and improved cardiac function. CO-mediated
SDF-1α expression and Akt-dependent up-regulation of the
transcription factor AP-2α is essential for CO-induced expres-
sion of CXCL12 and myocardial repair after ischaemic injury
(Lin et al., 2013). Furthermore, the anti-apoptotic behaviour
of CO is attributed to the inhibition of mitochondrial mem-
brane permeabilization, a key event in the intrinsic apoptotic
pathway. In isolated non-synaptic mitochondria, CO par-
tially inhibited loss of potential, mPTP opening, swelling and
cytochrome c release (Queiroga et al., 2010).
The most salient feature of CO-mediated cytoprotection is
the suppression of inflammation and cell death. One of the
important cellular targets of CO is the macrophage. Exposure
of macrophages to CO results in the generation of an anti-
inflammatory phenotype that leads to and preserves cellular
homeostasis at the site of injury (Chin et al., 2007).
Pretreatment of endothelial cells with CORM-2 resulted
in the decrease of LPS-induced production of ROS and NO,
up-regulation of HO-1, decrease in iNOS, inhibition of NF-κB
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and downregulation of expression of intercellular adhesion
molecule 1 (ICAM-1) (Sun et al., 2008). Cardiac cells pre-
treated with CORM-3 were more resistant to the damage
caused by hypoxia-reoxygenation and oxidative stress. Car-
dioprotection was lost when CORM-3 was replaced by an
inactive form (iCORM-3) that is incapable of liberating CO
(Clark et al., 2003). When interpreting data from studies
using CORM-2 and CORM-3, it should be kept in mind that
these agents while releasing CO, also release ROS (Marazioti
et al., 2011).
Concerning the effect of CO on PC, studies in isolated
hearts have shown that exposure to CO alters or raises the
ischaemic tolerance. PC accelerated the development of
ischaemic contracture, increased the pre-ischaemic coronary
flow and improved contractility, whereas CO exposure
increased the baseline coronary flow and the contracture
magnitude, improved both contractile recovery and ventricu-
lar arrhythmia incidence, and increased the hyperaemic coro-
nary flow. Thus, CO-exposed hearts could be preconditioned
in the same way as normal myocardium (Rochetaing et al.,
2001). When rat isolated hearts subjected to I/R and treated
with CORM2, they exhibited significant reduction in post-
ischaemic levels of the myocardial injury markers CK and
LDH. Moreover, CORM-2 showed significantly improved
post-ischaemic recovery of heart rate, coronary flow rate,
cardiodynamic parameters and reduced infarct size (Soni
et al., 2012). PC with CORM-2 in rat isolated hearts markedly
decreased LDH and CK levels in coronary effluent after global
ischaemia, providing also a significant improvement in coro-
nary flow rate, heart rate, cardiodynamic parameters and
marked attenuation in infarct size (Soni et al., 2010). In addi-
tion, marked LV dysfunction following coronary artery occlu-
sion and reperfusion was ameliorated by CORM-3 in mouse
hearts (Clark et al., 2009).
The mechanism by which CORM-2 triggers PC in rat
isolated hearts is probably due to the activation of the p38
MAPK β and PKC pathways before ischaemia as well as PI3-
kinase pathway during reperfusion (Soni et al., 2012) and
activation of the KATP channels (Soni et al., 2010).
Concerning the effect of CO on PostC, perfusion with
CORM-2 during the first 10 min of reperfusion inhibited the
release of LDH and CK, and reduced the infarct size in iso-
lated hearts (Mei et al., 2007). When isolated hearts were
reperfused in the presence of CORM-3 after an ischaemic
event, their myocardial performance was significantly
improved and infarct size was reduced, whereas cardioprotec-
tion was lost when CORM-3 was replaced by an inactive form
(iCORM-3) (Clark et al., 2003). Cardioprotective effects of
both CORM-2 and CORM-3 during reperfusion were probably
mediated through activation of mitoKATP channels (Clark
et al., 2003; Mei et al., 2007). Furthermore, cardioprotection
by CO could also involve the NOS-cGMP and HO-1 pathways
(Mei et al., 2007).
In conclusion, although CO is essential to the triggering
of PC and PostC in in vitro models of ischaemia/reperfusion,
further studies are required to elucidate the mechanisms
regulating its cardioprotective effects.
In vivo studies. CORM-3 induces delayed protection against
myocardial infarction in an in vivo model of ischaemia/
reperfusion. Pre-treatment with CORM-3 24 h prior to coro-
nary occlusion markedly reduced infarct size, and the infarct-
sparing effect of CORM-3 was still evident 72 h after
administration of the CO donor, showing that CORM-3
induced delayed protection against myocardial infarction,
which was similar to that afforded by the late phase of PC
(Stein et al., 2005). Using the same CO-releasing molecule as
above, the same authors showed that pre-treatment with
CORM-3 in mice resulted in a significant reduction in
markers of apoptosis after I/R injury. CORM-3 triggered a
cardioprotective signalling cascade that recruited the tran-
scription factors NF-κB, STAT1/3 and Nrf2 with a subsequent
increase in cardioprotective and anti-apoptotic molecules in
the myocardium, leading to the late PC-mimetic infarct-
sparing effects (Stein et al., 2012).
However, only one study until now has investigated the
cardioprotective effects of CO in a large animal model of I/R.
Pre-treatment with low-dose CO 120 min before regional
ischaemia and reperfusion did not provide acute protection
as indicated by metabolic, energy-related and injury markers
in pigs. The cardioprotective effects of CO either require
higher doses or occur later after reperfusion (Ahlström et al.,
2011). The beneficial effects of endogenous CO and exog-
enous CO administration in cardioprotection are shown in
Table 3.
In conclusion, there are only a limited number of studies
regarding the cardioprotective effects of exogenous adminis-
tration of CO in in vivo ischaemia–reperfusion models. Fur-
thermore, to the best of our knowledge, there is no study that
investigates the effect of CO in triggering PostC in an in vivo
model of ischaemia/reperfusion.
Human studies. Endogenous CO at physiological concentra-
tions is cytoprotective, whereas excess levels reflect underly-
ing oxidative stress, inflammation and vascular pathology
and indicate adverse clinical sequelae. However, the relation
of exhaled CO to metabolic/vascular risk in the community is
unknown (Cheng et al., 2010). Most of the clinical studies up
to now have investigated the role of CO as a poison in
humans. Functionally, excess endogenous CO can lead to the
formation of ROS, (Zhang and Piantadosi, 1992) can impair
NO-mediated vasodilation (Durante, 2002) and can promote
adverse vascular remodelling (Peyton et al., 2002).
Although there are no clinical studies with drugs that
liberate CO, we should mention that widely used drugs such
as statins and fibrates have been shown to activate HO-1.
HO-1 exerts multifunctional roles in the CVS, it cooperates
with its downstream products, CO and bilirubin, to exert
diverse cellular protective effects and provide potential thera-
peutic targets. Simvastatin has been shown to induce HO-1 in
human smooth muscle cells (Lee et al., 2004). Blocking HO-1
activity by zinc protoporphyrin or a small interfering RNA
decreased the anti-inflammatory effect of simvastatin
through inhibition of NO production, NF-κB activation and
p21. The Akt and p38 MAPK pathways appeared to mediate
the effect of simvastatin on HO-1 induction. This finding
suggests that statins may provide a new therapeutic approach
to the activation of HO-1.
Moreover, fenofibrate, rosiglitazone and troglitazone,
which are ligands of the PPAR, also increase the expression of
HO-1 in smooth muscle (Kronke et al., 2007). Other pharma-
cological agents, such as curcumin, resveratrol, cyclosporine,
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Table 3
The beneficial effects of endogenous and exogenous CO in ischaemia/reperfusion injury, in PC and PostC
Experimental model Effect of CO Proposed mechanism(s) Reference
Cardiomyocytes (HO-1 expression) –
treatment with haemin and
bilirubin
Protective against reoxygenation
damage
Attenuation of ROS Foresti et al. (2001)
HL-1 cells – gene delivery of HIF-1α Cardioprotection Depended upon HO activity indicating
that downstream to HO-1, bilirubin
and CO may be organ effectors
Czibik et al. (2009)
HO-1 overexpression Protects the myocardium from
ischaemic and reperfusion injury
Yet et al. (2001)
Dahl salt-sensitive (SD) rats Cardioprotection by promoting
coronary vasodilatation
HO-1 expression is increased Johnson et al.
(2004)
H9c2 cells (CO) Prevention of apoptosis CO induces mitochondrial generation
of O2, which is converted by SOD to
H2O2, and the subsequent Akt
activation by H2O2 attenuates
apoptosis during
ischaemia–reperfusion
Kondo-Nakamura
et al. (2010)
Neonatal cardiomyocytes and H9C2
cardiomyoblasts (CO and CORM-2)
Enhancement of neovascularization in
the myocardium in the peri-infarct
region and improvement of cardiac
function
CO-mediated CXCL12 expression and
Akt-dependent up-regulation
Lin et al. (2013)
Cardiac cells (pre-treatment with
CORM-3)
Resistant to the damage caused by
hypoxia-reoxygenation and
oxidative stress
Cardioprotection was lost when
CORM-3 was replaced by an inactive
form (iCORM-3) that is incapable of
liberating CO
Clark et al. (2003)
HUVEC (pre-treatment with CORM-2) Preconditioning Decrease of LPS-induced production of
ROS and NO, up-regulation of
HO-1, decrease of iNOS, inhibition
of LPS-induced activation of NF-κB
and down-regulation of expression
of ICAM-1
Sun et al. (2008)
Rat isolated hearts (CO exposure) Increased the baseline coronary flow
and the contracture magnitude,
improved contractile recovery and
ventricular arrhythmia incidence,
and increased the hyperemic
coronary flow
CO-exposed hearts could be
preconditioned in the same way as
normal myocardium
Rochetaing et al.
(2001)
Rat isolated hearts (PC with CORM-2) Reduction of infarct size Activation of the p38 MAPK β and PKC
pathways before ischaemia and of
PI3-kinase pathway during
reperfusion
Soni et al. (2012)
Rat isolated hearts (PC with CORM-2) Marked attenuation of infarct size Activation of the KATP channels Soni et al. (2010)
Mouse hearts (CORM-3) Amelioration of LV dysfunction Clark et al. (2009)
Isolated hearts (CORM-3) Reduction in cardiac muscle damage
and infarct size
Activation of mitoKATP channels Clark et al. (2003)
Isolated hearts (CORM-2) Reduction of infarct size Activation of mitoKATP channels –
NOS-cGMP and HO-1 pathways
Mei et al. (2007)
In vivo (mice) CORM-3 (24 h prior to
coronary occlusion)
Reduction of infarct size Delayed protection against myocardial
infarction which is similar to that
afforded by the late phase of PC
Stein et al., 2005
In vivo (mice) CORM-3-pre-teatment Reduction in markers of apoptosis
after I/R injury
NF-κB, STAT1/3 and Nrf2 with a
subsequent increase in
cardioprotective and anti-apoptotic
molecules
Stein et al. (2012)
In vivo (porcine) pre-treatment with
low-dose CO
No protection as indicated by
metabolic, energy-related and
injury markers
Ahlström et al.
(2011)
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rapamycin and probucol, have also been shown to induce
HO-1 (Abraham and Kappas, 2008).
In conclusion, there is no large-scale clinical study pro-
viding solid evidence for the usefulness of therapy based on
HO-1 in patients. As both CO and bilirubin play important
roles in cardiovascular protection, the potential of these
chemicals as clinical therapeutics as compared with HO-1 are
still unclear and needs to be studied further.
Conclusions and future perspectives
In this review, we provided an overview of the recent
advances in our knowledge on endogenously produced or
pharmacologically administered NO, H2S and CO in cardio-
protection. Figure 1 summarizes the effects of the gasotrans-
mitters on the major signalling pathways mediating
cardioprotection. Table 4 summarizes the effect of gasotrans-
mitters on I/R injury and cardioprotection by different con-
ditioning strategies.
NO is an important component of several cardioprotec-
tive signalling cascades. Accordingly, NO donor molecules
and compounds that activate NO-independent-cGMP-
mediated signalling pathways are promising tools for cardio-
protection in the clinical arena. For example, nitrite anion
has emerged as a promising cardioprotective agent due to its
ability to be reduced to NO in the ischaemic heart with an
acidic environment. However, excess NO accumulation
during ischaemia may contribute to reperfusion injury via
nitrosative stress due to excess superoxide and the conse-
quent peroxynitrite formation.
H2S has recently come to the fore due to some promising
data demonstrating that this gasotransmitter confers cardio-
protection in a variety of settings. Both endogenously gener-
Figure 1
Schematic diagram showing major signalling cellular pathways of gasotransmitters NO (blue cloud), H2S (yellow cloud) and CO (black cloud).
ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; GSK3β, glycogen synthase kinase 3β; KATP, ATP-dependent potassium channel; mPTP
mitochondrial permeability transition pore; sGC, soluble guanylyl cyclase.
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ated H2S and exogenously supplied H2S reduce infarct size
and improve heart function following I/R injury. Transla-
tional efforts aiming to move basic research findings into the
clinical arena are underway with H2S-releasing molecules.
CO is the least studied one of the three gasotransmitters
in the context of ischaemic and pharmacological condition-
ing. Although HOs exert beneficial effects in I/R injury, the
contribution of CO to this effect is not entirely clear. Never-
theless, some CORMs have been developed for cardioprotec-
tion; however, these molecules have not reached the clinical
phase yet. Along with the excitement for the potential thera-
peutic use of CO comes the concern for its toxicity, as expo-
sure to excess exogenous CO either acutely or chronically via
air pollution has profound deleterious effects on cardiac
function.
Findings from other research niches in the cardiovascular
system have highlighted the importance of gasotransmitter
crosstalk, suggesting that in I/R injury and cardioprotection,
the role of gasotransmitters is worth investigating in an inte-
grated way. Indeed, in angiogenesis and vasodilation, gas-
otransmitter pathways converge into common downstream
effectors. Thus, successful therapeutic strategies might need
to utilize more than one gasotransmitters or their pharmaco-
logical modulators.
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